Myosin Therapeutics Secures $3M in Second Seed Funding to Advance Brain Cancer and Addiction Therapies
Key Insights
Myosin Therapeutics (search) has raised over $3 million in its second seed round, complementing NIH funding to advance clinical trials for glioblastoma (search) and methamphetamine use disorder (search) treatments.
The company's lead compound MT-125, which targets molecular nanomotors to block tumor growth, has received FDA orphan drug designation for malignant gliomas (search) and will enter Phase 1b trials.
MT-110, the company's novel treatment for methamphetamine use disorder (search), is set to begin Phase 1 clinical trials, addressing a critical gap in FDA-approved treatments for this condition.
Jupiter, Florida-based Myosin Therapeutics (search) has secured over $3 million in its second seed funding round, positioning the company to advance its innovative pipeline of cancer and neuroscience therapies into clinical trials. The funding round, supplemented by National Institutes of Health support, attracted investment from prominent healthcare venture firms and strategic partners.
The company's flagship program centers on MT-125, a novel compound targeting molecular nanomotors to combat glioblastoma (search), one of the most aggressive forms of brain cancer. With current treatments offering limited efficacy and an average survival time of only 8 months, MT-125 represents a potential breakthrough in addressing this devastating disease. The FDA has already recognized the compound's promise by granting it orphan drug designation for malignant gliomas (search).
"This funding is pivotal as it will allow us to initiate multiple clinical trials this year, including a Phase 1b trial for MT-125 in glioblastoma (search) patients," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics (search). The company's innovative approach focuses on blocking both tumor growth and invasion through its unique molecular mechanism.
Strategic Investment Partners
The funding round was led by returning investors DeepWork Capital (search), Florida Opportunity Fund, and Mint12 Pharma, with new participation from Dynagrow Capital, Mayo Clinic Ventures, and The Sontag Innovation Fund. Dave Adams, co-Founder of Mint12 Pharma, expressed confidence in the company's trajectory, noting, "Myosin Therapeutics (search) exemplifies a well-run organization, consistently achieving key milestones to advance MT-125 and MT-110."
Expanding into Addiction Treatment
Beyond oncology, Myosin Therapeutics (search) is developing MT-110 for methamphetamine use disorder (search) (MUD), addressing a significant unmet medical need. Despite millions worldwide suffering from MUD, there are currently no FDA-approved treatments available. The new funding will enable the company to initiate Phase 1 clinical trials for MT-110, potentially offering the first approved therapeutic option for this challenging condition.
Scientific Foundation and Future Direction
The company, which emerged from The Herbert Wertheim UF Scripps Institute, leverages its proprietary platform targeting molecular nanomotor (search) proteins to develop therapeutic solutions. This unique approach has positioned Myosin Therapeutics (search) at the forefront of both oncology and neuroscience drug development, with potential applications across multiple devastating diseases.